Regulation - Merck & Co, Diabetes

Filter

Current filters:

Merck & CoDiabetes

Popular Filters

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat

20-01-2014

Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs

26-07-2013

Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

First IQWiG assessment of the established drug market finds advantage for Januvia

15-07-2013

There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin)…

DiabetesEuropeMerck & CoPharmaceuticalPricingRegulation

American Diabetes Association calls for independent review of incretin-based therapy

12-06-2013

The American Diabetes Association is asking all pharmaceutical companies involved in the development…

DiabetesJanuviaMerck & CoPharmaceuticalRegulationResearch

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

09-11-2012

US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

GlaxoSmithKline readies for filing of diabetes drug albiglutide on positive final data

12-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that positive data from the Phase III Harmony 8 study…

albiglutideDiabetesGlaxoSmithKlineJanuviaMerck & CoPharmaceuticalRegulationResearch

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk

10-04-2012

The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

Merck warned for not carrying out post-approval sitagliptin study

28-02-2012

The US Food and Drug Administration (FDA) has sent a warning letter to Merck & Co for failing to carry…

DiabetesJanumetJanuviaMerck & CoPharmaceuticalRegulationsitagliptinSitagliptin Metformin HCL

Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study

15-11-2011

The European Medicines Agency says it has been formally notified by Merck Sharp & Dohme (Europe), a subsidiary…

Cardio-vascularDiabetesJanactiMerck & CoPharmaceuticalPioglitazoneRegulationResearchsitagliptinvorapaxar

Merck & Co debuts Nexplanon in USA; gets negative FDA response on Zoely and Saflutan

10-11-2011

Merck & Co (NYSE; MRK), the USA’s second largest drugmaker, says that its Nexplanon (etonogestrel…

DiabetesJanuviaMarkets & MarketingMerck & CoNexplanonOphthalmicsPharmaceuticalRegulationReproductiveResearchSaflutanZoely

FDA clears Merck & Co’s combo diabetes/cholesterol therapy Juvisync

10-10-2011

The US Food and Drug Administration on Friday approved the marketing of the first combination drug to…

Cardio-vascularDiabetesJanuviaJuvisyncMerck & CoNorth AmericaPharmaceuticalRegulationZocor

Back to top